XIENCE V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study (XIENCE V USA Long Term Follow-up Cohort).
Phase of Trial: Phase IV
Latest Information Update: 01 Jul 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms XVU-LTF
- Sponsors Abbott Laboratories
- 13 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Oct 2011 Planned end date changed from 1 Mar 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 09 May 2011 Planned end date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov